ES2587256T3 - Derivados de la benzamida y su uso como inhibidores de HSP90 - Google Patents

Derivados de la benzamida y su uso como inhibidores de HSP90 Download PDF

Info

Publication number
ES2587256T3
ES2587256T3 ES11726470.5T ES11726470T ES2587256T3 ES 2587256 T3 ES2587256 T3 ES 2587256T3 ES 11726470 T ES11726470 T ES 11726470T ES 2587256 T3 ES2587256 T3 ES 2587256T3
Authority
ES
Spain
Prior art keywords
group
alkyl
phenyl
piperidin
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11726470.5T
Other languages
English (en)
Spanish (es)
Inventor
Alastair David Graham Donald
Joanne Mcdermott
Sanjay Ratilal Patel
David Festus Charles Moffat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chroma Therapeutics Ltd
Original Assignee
Chroma Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chroma Therapeutics Ltd filed Critical Chroma Therapeutics Ltd
Application granted granted Critical
Publication of ES2587256T3 publication Critical patent/ES2587256T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES11726470.5T 2010-06-11 2011-06-10 Derivados de la benzamida y su uso como inhibidores de HSP90 Active ES2587256T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201009853 2010-06-11
GBGB1009853.1A GB201009853D0 (en) 2010-06-11 2010-06-11 HSP90 inhibitors
PCT/GB2011/000879 WO2011154708A1 (en) 2010-06-11 2011-06-10 Benzamide derivatives and their use as hsp90 inhibtors

Publications (1)

Publication Number Publication Date
ES2587256T3 true ES2587256T3 (es) 2016-10-21

Family

ID=42471553

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11726470.5T Active ES2587256T3 (es) 2010-06-11 2011-06-10 Derivados de la benzamida y su uso como inhibidores de HSP90

Country Status (18)

Country Link
US (2) US9321718B2 (enExample)
EP (1) EP2580193B1 (enExample)
JP (1) JP5955317B2 (enExample)
KR (1) KR20130112026A (enExample)
CN (1) CN103068799B (enExample)
AU (1) AU2011263543B2 (enExample)
BR (1) BR112012031634A2 (enExample)
CA (1) CA2802279A1 (enExample)
DK (1) DK2580193T3 (enExample)
EA (1) EA021237B1 (enExample)
ES (1) ES2587256T3 (enExample)
GB (1) GB201009853D0 (enExample)
IL (1) IL223514A (enExample)
MX (1) MX341341B (enExample)
NZ (1) NZ605558A (enExample)
SG (1) SG186232A1 (enExample)
WO (1) WO2011154708A1 (enExample)
ZA (1) ZA201300036B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201211310D0 (en) 2012-06-26 2012-08-08 Chroma Therapeutics Ltd CSF-1R kinase inhibitors
SI2909175T1 (sl) 2012-10-17 2017-08-31 Macrophage Pharma Limited Terc-butil-n-(2-(4-(6-amino-5-(2,4-difluorobenzoil)-2-oksopiridin-1 (2h)-il)-3,5-difluorofenil)etil)-l-alaninat ali njegova sol, hidrat ali solvat
CN102924318B (zh) * 2012-11-26 2014-06-04 武汉大学 阻断h5n1禽流感病毒进入的l-亮氨酸衍生物及其制备方法
WO2017131500A1 (ko) * 2016-01-29 2017-08-03 계명대학교 산학협력단 Hsp90 억제 활성을 갖는 신규 화합물 또는 이의 약제학적으로 허용가능한 염 및 이의 의학적 용도
WO2019027203A1 (ko) * 2017-08-02 2019-02-07 계명대학교 산학협력단 Ｈｓｐ９０ 억제 활성을 갖는 디히드록시페닐계 입체이성질체 및 이의 의학적 용도
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
AU2019417833B2 (en) * 2018-12-31 2024-11-07 Biomea Fusion, Inc. Irreversible inhibitors of menin-MLL interaction
US11174263B2 (en) 2018-12-31 2021-11-16 Biomea Fusion, Inc. Inhibitors of menin-MLL interaction
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
EP4387972A1 (en) 2021-08-20 2024-06-26 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2024155710A1 (en) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK1769679T3 (da) 2004-07-16 2011-04-26 Ishihara Sangyo Kaisha Baktericid sammensætning til landbrugsmæssig eller havebrugsmæssig anvendelse samt fremgangsmåde til bekæmpelse af plantesygdom
JP2008525243A (ja) * 2004-12-29 2008-07-17 ハネウェル・インターナショナル・インコーポレーテッド 耐湿性ｐｂｏ繊維およびその物品ならびにその製造方法
BRPI0607739A2 (pt) 2005-02-25 2009-09-29 Serenex Inc derivados de tetraidroindolona e tetraidroindazolona, composição compreendendo os mesmos e uso relacionado
CA2604042C (en) * 2005-04-13 2016-06-21 Astex Therapeutics Limited Pharmaceutical compounds
CA2605985A1 (en) * 2005-05-03 2006-11-09 Pfizer Inc. Amide resorcinol compounds
US20090215800A1 (en) 2005-05-05 2009-08-27 Chroma Therapeutics Ltd Enzyme and Receptor Modulation
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
US20080076800A1 (en) 2006-08-24 2008-03-27 Huang Kenneth H Benzene, Pyridine, and Pyridazine Derivatives
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
US8916552B2 (en) * 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
WO2008053319A1 (en) * 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
GB0803747D0 (en) 2008-02-29 2008-04-09 Martin Enzyme and receptor modulation
GB0806527D0 (en) * 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ZA201300036B (en) 2013-09-25
MX341341B (es) 2016-08-17
CA2802279A1 (en) 2011-12-15
AU2011263543B2 (en) 2014-10-02
KR20130112026A (ko) 2013-10-11
US20130143926A1 (en) 2013-06-06
SG186232A1 (en) 2013-01-30
EA021237B1 (ru) 2015-05-29
CN103068799A (zh) 2013-04-24
CN103068799B (zh) 2014-09-03
JP5955317B2 (ja) 2016-07-20
EP2580193A1 (en) 2013-04-17
AU2011263543A1 (en) 2013-01-10
WO2011154708A1 (en) 2011-12-15
MX2012014506A (es) 2013-02-07
US20160193200A1 (en) 2016-07-07
GB201009853D0 (en) 2010-07-21
EA201270816A1 (ru) 2013-04-30
IL223514A0 (en) 2013-03-05
IL223514A (en) 2016-07-31
EP2580193B1 (en) 2016-07-20
US9321718B2 (en) 2016-04-26
BR112012031634A2 (pt) 2016-11-08
JP2013533229A (ja) 2013-08-22
NZ605558A (en) 2014-11-28
DK2580193T3 (en) 2016-09-05

Similar Documents

Publication Publication Date Title
ES2587256T3 (es) Derivados de la benzamida y su uso como inhibidores de HSP90
ES2275675T3 (es) Compuestos y metodos para tratar la enfermedad de alzheimer.
ES2252257T3 (es) Compuestos para tratar la enfermedad de alzheimer.
ES2336009T3 (es) Inhibidores de la ns-3 serina proteasa del vhc.
ES2522617T3 (es) Derivados de piperidina/piperazina
AU2003225730A1 (en) Substituted hydroxyethylamines
JP2004502669A (ja) アルツハイマー病を治療するための化合物
CA2327282A1 (en) Treatment of parasitic diseases by inhibition of cysteine proteases of the papain superfamily
ES2261699T3 (es) Macrociclos utiles en el tratamiento de la enfermedad de alzheimer.
KR100793095B1 (ko) Ｂａｃｅ 저해효능을 가진 신규한 술폰 아미드 유도체
MXPA05005649A (es) Ureas y carbamatos sustituidos.
AU2002360403A1 (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of Alzheimer's disease
WO2018085921A1 (en) CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN
US8735622B2 (en) Histone demethylase inhibitors and methods for using the same
CN103387601A (zh) 抗登革热病毒(denv)杂环肽类化合物及其制备方法和用途
Dahlgren et al. New inhibitors of the malaria aspartyl proteases plasmepsin I and II
AU2006243393A1 (en) 3 -mono- and 3 , 5-disubstituted piperidine derivatives as renin inhibitors
KR100696139B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체 및그의 제조방법
US20090156825A1 (en) Fluorescent compounds that bind to histone deacetylase
EP1537072A1 (en) Substituted aminoethers for the treatment of alzheimer s disease
BR112021010704A2 (pt) Composto macrocíclico e uso do mesmo
JP6410371B2 (ja) 環状ペプチド化合物、その製造方法、医薬組成物および使用
JP2005505517A (ja) アルツハイマー病を治療するためのアミンジオール
KR100814092B1 (ko) 히스톤 디아세틸라제 저해활성을 갖는 알킬카바모일나프탈렌일옥시 옥테노일 하이드록시아마이드 유도체, 이의제조방법 및 이를 유효성분으로 하는 항암제용 약학조성물
JP2005536448A (ja) アミン１，２−及び１，３−ジオール化合物、及びアルツハイマー病を治療するためのその使用